menu
    • menu
    [{"orgOrder":0,"company":"Channel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CT2000","moa":"NaV1.7 channel","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Channel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Channel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Channel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Channel Therapeutics","sponsor":"Pelthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Channel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Channel Therapeutics \/ Pelthos Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Channel Therapeutics \/ Pelthos Therapeutics"},{"orgOrder":0,"company":"Channel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Channel Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Channel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Channel Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Channel Therapeutics

    Menu

    Channel Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Channel Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Channel Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Pelthos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Pelthos Therapeutics Completes Merger with Channel Therapeutics

                            Details : The combined company plans to launch Zelsuvmi (berdazimer) topical gel, a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum.

                            Product Name : Zelsuvmi

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 02, 2025

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Pelthos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Channel Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Channel Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT2000

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Channel Therapeutics Shows Eye Pain Efficacy of NaV1.7 Inhibitor in Preclinical

                            Details : Channel has achieved its predefined endpoints in two pre-clinical animal models of eye drop formulations, CT2000, for the treatment of both acute ocular pain as well as chronic ocular surface pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : CT2000

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Channel Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Channel Therapeutics

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Channel Therapeutics Announces Positive Data for NaV1.7 Inhibitor Depot Formulation

                            Details : NaV1.7 inhibitor is being developed for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth